Central retinal artery occlusion after intravitreal brolucizumab injection for treatment-naïve neovascular age-related macular degeneration; a case report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Sung Hwa | - |
dc.contributor.author | Kim, Hoon Dong | - |
dc.date.accessioned | 2024-06-12T02:30:55Z | - |
dc.date.available | 2024-06-12T02:30:55Z | - |
dc.date.issued | 2024-04 | - |
dc.identifier.issn | 1471-2415 | - |
dc.identifier.issn | 1471-2415 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26422 | - |
dc.description.abstract | Background To report a case of central retinal artery occlusion (CRAO) after intravitreal injection of brolucizumab for a treatment-na & iuml;ve neovascular age-related macular degeneration (nAMD) patient without comorbid cardiovascular disease history.Case presentation A 79-year-old Asian male without a cardiovascular disease history such as diabetes or hypertension underwent three times of monthly consecutive intravitreal brolucizumab injections for treatment of progressed nAMD in his left eye. Two days after the third injection, the patient presented with acute painless visual loss. Typical retinal whitening with a cherry red spot was observed on the fundus photograph, and retinal swelling with hyper-reflectivity was also identified on the optical coherence tomography (OCT) scan. On the fundus fluorescein angiography, arm-to-retina time and arteriovenous transit time were remarkedly delayed, but clinical findings suggesting an intraocular inflammation (IOI) were not observed. Therefore, CRAO was diagnosed, and anterior chamber paracentesis was administrated immediately. However, there had been no improvement in visual acuity during the follow-up period of three months, despite prolonged oral steroid and anti-platelet agent medication.Conclusions In rare cases, patients without cardiovascular comorbidities can develop CRAO after intravitreal brolucizumab injection without gross evidence of IOI. Therefore, CRAO should always be in consideration and careful observation is required after intravitreal brolucizumab injection for nAMD patients with old age, even if the patient does not have any other cardiovascular disease history. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BMC | - |
dc.title | Central retinal artery occlusion after intravitreal brolucizumab injection for treatment-naïve neovascular age-related macular degeneration; a case report | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1186/s12886-024-03452-3 | - |
dc.identifier.scopusid | 2-s2.0-85191685593 | - |
dc.identifier.wosid | 001209745600001 | - |
dc.identifier.bibliographicCitation | BMC OPHTHALMOLOGY, v.24, no.1 | - |
dc.citation.title | BMC OPHTHALMOLOGY | - |
dc.citation.volume | 24 | - |
dc.citation.number | 1 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Ophthalmology | - |
dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
dc.subject.keywordAuthor | Age-related macular degeneration | - |
dc.subject.keywordAuthor | Brolucizumab | - |
dc.subject.keywordAuthor | Central retinal artery occlusion | - |
dc.subject.keywordAuthor | Intraocular inflammation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.